Periodontal treatment effects on endothelial function and cardiovascular disease biomarkers in subjects with chronic periodontitis: protocol for a randomized clinical trial
Periodontal disease (PD) is an infectious clinical entity characterized by the destruction of supporting tissues of the teeth as the result of a chronic inflammatory response in a susceptible host. It has been proposed that PD as a subclinical infection may contribute in the etiology and pathogenesis of several systemic diseases including Atherosclerosis.
A number of epidemiological studies link periodontal disease/edentulism as independent risk factors for acute myocardial infarction, peripheral vascular disease, and cerebrovascular disease. Moreover, new randomized controlled clinical trials have shown an improvement on cardiovascular surrogate markers (endothelial function) after periodontal treatment.
Nonetheless, such trials are still limited in terms of external validity, periodontal treatment strategies, CONSORT-based design and results consistency/extrapolation. The current study is designed to evaluate if periodontal treatment with scaling and root planning supplemented with chlorhexidine improves endothelial function and other biomarkers of cardiovascular disease in subjects with moderate to severe periodontitis.
Methods:
This randomized, single-blind clinical trial will be performed at two health centers and will include two periodontal treatment strategies.
After medical/periodontal screening, a baseline endothelium-dependent brachial artery flow-mediated dilatation (FMD) and other systemic surrogate markers will be obtained from all recruited subjects. Patients then will be randomized to receive either supragingival/subgingival plaque cleaning and calculus removal plus chlorhexidine (treatment group) or supragingival plaque removal only (control group).
A second and third FMD will be obtained after 24 hours and 12 weeks of periodontal treatments, respectively. Each group will consist of 49 patients (n=98) and all patients will be followed-up for secondary outcomes and will be monitored through a coordinating center.
The primary outcomes are FMD differences baseline, 24 hours and 3 months after randomization. The secondary outcomes are differences in C-reactive protein (hs-CRP), glucose serum levels, blood lipid profile, and HOMA index.DiscussionThis RCT is expected to provide more evidence on the effects of different periodontal treatment modalities on FMD values, as well as to correlate such findings with different surrogate markers of systemic inflammation with cardiovascular effects.ClinicalTrials.gov Identifier: NCT00681564.
Author: Jorge RamirezRoger ArceAdolfo Contreras
Credits/Source: Trials 2011, 12:46
Published on: 2011-02-16
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
